

## **Product datasheet for TF320659**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **AAK1 Human shRNA Plasmid Kit (Locus ID 22848)**

**Product data:** 

**Product Type:** shRNA Plasmids

Product Name: AAK1 Human shRNA Plasmid Kit (Locus ID 22848)

**Locus ID:** 22848

**Vector:** pRFP-C-RS (TR30014)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Retroviral plasmids

**Components:** AAK1 - Human, 4 unique 29mer shRNA constructs in retroviral RFP vector(Gene ID = 22848).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRFP-C-RS Vector, TR30015, included for free.

**RefSeq:** BC002695, NM 014911, NM 014911.1, NM 014911.2, NM 014911.3, BC002695.2, BC073953,

BC090950, BC104842, BC111965, BC132937, BC132939, BC143710, NM 014911.4

UniProt ID: Q2M218

**Summary:** This gene encodes a member of the SNF1 subfamily of serine/threonine protein kinases.

Adaptor-related protein complex 2 (AP-2 complexes) functions during receptor-mediated endocytosis to trigger clathrin assembly, interact with membrane-bound receptors, and recruit encodytic accessory factors. The encoded protein interacts with and phosphorylates a subunit of the AP-2 complex, which promotes binding of AP-2 to sorting signals found in membrane-bound receptors and subsequent receptor endocytosis. Its kinase activity is stimulated by clathrin. This kinase has been shown to play an important role in regulating the clathrin-mediated endocytosis of the rabies virus, facilitating infection. Inhibitors of this kinase are being studied as candidate therapeutics to disrupt the entry of viruses, including SARS-CoV-2, into target cells. It is also involved in positive regulation of Notch pathway signaling in mammals. Alternatively spliced transcript variants have been described, but their

biological validity has not been determined. [provided by RefSeq, Aug 2020]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).